Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorMedical
Phone301-838-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$408.90 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) announced its quarterly earnings results on Tuesday, February, 26th. The specialty pharmaceutical company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.29 by $0.19. The specialty pharmaceutical company earned $113.50 million during the quarter, compared to analyst estimates of $105.36 million. Supernus Pharmaceuticals had a return on equity of 27.45% and a net margin of 27.14%. Supernus Pharmaceuticals's quarterly revenue was up 31.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.26 earnings per share. View Supernus Pharmaceuticals' Earnings History.
When is Supernus Pharmaceuticals' next earnings date?
What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?
Supernus Pharmaceuticals issued an update on its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435-455 million, compared to the consensus revenue estimate of $456.02 million.
What price target have analysts set for SUPN?
7 brokerages have issued 1-year price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $44.00 to $65.00. On average, they expect Supernus Pharmaceuticals' share price to reach $57.4286 in the next year. This suggests a possible upside of 48.6% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.
What is the consensus analysts' recommendation for Supernus Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.
What are Wall Street analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (3/14/2019)
- 2. Cantor Fitzgerald analysts commented, "We anticipate the core Trokendi XR and Oxtellar XR businesses will continue to perform well, particularly the former, with the ongoing roll-out for the migraine prevention indication. Over the next 12-24 months, with provision of positive clinical trial data, we believe investors will better appreciate the value of pipeline assets the bipolar indication opportunity for Oxtellar XR. $57 price target is based on DCF and SOP analyses that forecast peak Oxtellar XR and Trokendi XR sales of $170 million (by 2026) and $450 million (2021) respectively." (2/27/2019)
- 3. Mizuho analysts commented, "We initiate coverage with a Buy rating and $61 PT. We believe Supernus is well-positioned in an attractive CNS market, with a promising pipeline that can drive growth through pending Trokendi XR competition in migraine." (9/17/2018)
Has Supernus Pharmaceuticals been receiving favorable news coverage?
Headlines about SUPN stock have been trending somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Supernus Pharmaceuticals earned a daily sentiment score of 1.1 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), West Pharmaceutical Services (WST), Neurocrine Biosciences (NBIX), SAGE Therapeutics (SAGE), Exelixis (EXEL), WILLIAM DEMANT/ADR (WILYY), Eurofins Scientific (ERFSF), BIO-TECHNE (TECH), NMC HEALTH PLC/ADR (NMHLY), Recordati (RCDTF), Loxo Oncology (LOXO), Marina Biotech (MRNA), Icon (ICLR), Masimo (MASI) and Carl Zeiss Meditec (AFX).
What other stocks do shareholders of Supernus Pharmaceuticals own?
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)
- Mr. Gregory S. Patrick, VP & CFO (Age 68)
- Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)
- Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)
- Dr. Todd Horich M.B.A., Ph.D., VP of Marketing
Who are Supernus Pharmaceuticals' major shareholders?
Supernus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (15.45%), FMR LLC (3.98%), Dimensional Fund Advisors LP (2.51%), Bank of New York Mellon Corp (2.31%), Fiera Capital Corp (1.80%) and Rothschild & Co. Asset Management US Inc. (1.63%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Which institutional investors are selling Supernus Pharmaceuticals stock?
SUPN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Ranger Investment Management L.P., Acadian Asset Management LLC, Mesirow Financial Investment Management Equity Management, Falcon Point Capital LLC, Alps Advisors Inc., Boston Advisors LLC and First Trust Advisors LP. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Insider Buying and Selling for Supernus Pharmaceuticals.
Which institutional investors are buying Supernus Pharmaceuticals stock?
SUPN stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Scout Investments Inc., WINTON GROUP Ltd, Macquarie Group Ltd., Candriam Luxembourg S.C.A., BlackRock Inc., SG Americas Securities LLC and Fiera Capital Corp. View Insider Buying and Selling for Supernus Pharmaceuticals.
How do I buy shares of Supernus Pharmaceuticals?
Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of SUPN stock can currently be purchased for approximately $38.65.
How big of a company is Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a market capitalization of $2.02 billion and generates $408.90 million in revenue each year. The specialty pharmaceutical company earns $110.99 million in net income (profit) each year or $2.05 on an earnings per share basis.
What is Supernus Pharmaceuticals' official website?
How can I contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]
MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
